FDA Issues Draft Guidance for Testing Psychedelics as Mental Health Treatments
The Food and Drug Administration recently released a draft guidance on research protocols for psychedelic substances. This move signals the probable use of these drugs as treatments for mood disorders such as post-traumatic stress disorder and depression. In a statement, Dr. Tiffany Farchione, who oversees the regulation of psychiatric medicines at the FDA, stated that psychedelics had shown promise as possible therapies for anxiety, substance use and mood disorders and added that they were still at the investigational stage. Farchione noted that the agency hoped to outline the issues that arose when developing psychedelic drug-development programs. The draft guidance, she…






